IN VIVO TEST SYSTEMS COMBINED CHEMOTHERAPIES AGAINST HIV

针对 HIV 的联合化疗体内测试系统

• 批准号: 2294764
• 负责人: MIKE MCCUNE
• 金额: $ 42.4万
• 依托单位: SYSTEMIX, INC.
• 依托单位国家: 美国
• 财政年份: 1990
• 资助国家: 美国
• 起止时间: 1990-08-01 至 1995-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2294764
• 关键词: VIVO; TEST; SYSTEMS; COMBINED; CHEMOTHERAPIES

The objective of these contracts is to maintain our capacity to test the efficacy of new anti-viral therapies in small, non-primate animal models; these contracts represent, in part, a recompetition of the small animal retrovirus models, with an expansion to include combinations of two drugs. Other initiatives will address non-human primate models. The present initiative will maintain our capacity to test efficacy of new therapies early in drug development. The variety of models available will allow the choice of model with appropriate molecular targets, such as those that are specific to HIV. The addition of a SCIDS mouse model reconstituted with human tissue and infected with HIV will allow efficacy to be measured directly against HIV in vivo. The inclusion of combination therapies in this initiative is especially important to the work of the Developmental Therapeutics Branch. Many of these therapies now in use or proposed for use in the clinical treatment of HIV infection in humans are limited in use because of toxicity. In an attempt to circumvent these toxicities, regimens combining more that one therapeutic agent are being proposed for clinical use; already a large number of clinical trials are underway or proposed to study AZT in combination with other drugs. With the recent identification and isolation of drug-resistant strains of HIV, use of combined therapies is likely to increase. Thus, there is a need to investigate the efficacy of new therapies in animal models and to extend those studies to include combinations that are likely to occur in the clinic.

这些合同的目的是保持我们测试的能力 新的抗病毒疗法在小型非青睐动物中的功效 模型；这些合同部分代表了小型的重新汇编 动物逆转录病毒模型，扩展以包括 两种药物。 其他举措将解决非人类灵长类动物模型。 本计划将保持我们测试功效的能力 药物开发早期的新疗法。 各种各样的模型 可用的将允许选择适当分子的模型 靶标，例如特定于艾滋病毒的目标。 添加 SCIDS小鼠模型与人体组织重构并感染了HIV 将允许在体内直接测量针对HIV的功效。 这 尤其是在此计划中纳入组合疗法 对发展治疗分支的工作很重要。 许多 这些疗法现在正在使用或提议用于临床治疗 由于毒性，人类的艾滋病毒感染受到限制。 在 试图规避这些毒性的尝试，将更多的方案结合在一起 正在提出一种治疗剂供临床使用； 已经是一个 正在进行大量临床试验或提议研究AZT 与其他药物结合。 与最近的识别和 抗药性艾滋病毒菌株的隔离，联合疗法的使用是 可能会增加。 因此，有必要调查功效 动物模型中的新疗法，并将这些研究扩展到包括 可能在诊所发生的组合。